Results 111 to 120 of about 5,281 (192)

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

PLOS Global Public Health
Induction of broad, durable immune responses is a challenge in HIV vaccine development. HVTN 100 Part A administered subtype C-containing ALVAC-HIV at months 0 and 1, and ALVAC-HIV with bivalent subtype C gp120/MF59 at months 3, 6 and 12.
Vimla Naicker, Fatima Laher, Linda-Gail Bekker, Kelly E Seaton, Mary Allen, Stephen De Rosa, Nicole L Yates, Nonhlanhla N Mkhize, Kevin Saunders, Jack Heptinstall, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Chenchen Yu, Tandile Modise, Valerie Bekker, Nicole Grunenberg, Briana Furch, Maurine D Miner, Sanjay Phogat, Carlos A Diazgranados, Sanjay Gurunathan, Marguerite Koutsoukos, Olivier Van Der Meeren, Alison C Roxby, Guido Ferrari, Lynn Morris, David Montefiori, M Juliana McElrath, Georgia D Tomaras, Zoe Moodie   +31 more
doaj   +1 more source

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.

Expert review of vaccines, 2011
Approximately 70 years passed between the licensing of alum salts as vaccine adjuvants and that of MF59™ MF59, an oil-in-water emulsion, is currently licensed for use in the elderly as an adjuvant in seasonal influenza vaccines. Its mechanism of action is not fully understood, but enhancement of the interaction between the antigen and the dendritic ...
openaire   +1 more source

RAD001-Adjuvanted Influenza Vaccine Synergizes With Anti-Programmed Cell Death Protein 1 Therapy to Enhance Antitumor Immunity in Programmed Cell Death Ligand 1-Low Murine Lung Cancer. [PDF]

World J Oncol
Ou HL, Sun J, Wu SB.
europepmc   +1 more source

Systematic Review of Safety of MF59-Adjuvanted Influenza Vaccine in Older Adults. [PDF]

Vaccines (Basel)
Manzotti ME, Bengolea A, Vazquez H.
europepmc   +1 more source

KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E. [PDF]

Front Immunol
Quan Y, Zhang S, Wang W, Wang Y, Xu K, Wang K, Wan W, Nie J.   +7 more
europepmc   +1 more source

Systemic Transcriptional Responses to Clinical Vaccine Formulations and Live-Attenuated Vaccination: Comparative Kinetics and Hypotheses for Therapeutic Cancer Vaccine Monitoring. [PDF]

Vaccines (Basel)
Goldman CK.
europepmc   +1 more source

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology. [PDF]

Hum Vaccin Immunother
Zarrinpanah T, Mashhadi Abolghasem Shirazi M, Modarressi SMH, Haghighat S.   +3 more
europepmc   +1 more source

Mapping the monoclonal antibody landscape of human cytomegalovirus. [PDF]

J Virol
McClave MK, Heldwein EE.
europepmc   +1 more source

Progress and prospects for herpesvirus vaccination using gB antigens. [PDF]

Front Immunol
English S, Khan-Qureshi A, Douglas AD.
europepmc   +1 more source

Investigating the In Vitro Immunomodulatory Potential of Microparticulate β-L-Adenosine in Particulate Vaccine Candidates. [PDF]

Vaccines (Basel)
Akkineni S, Pasupuleti D, Gulani MA, Harsoda Y, D'Souza MJ, Chbib C, Uddin MN.   +6 more
europepmc   +1 more source